These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 3933395)

  • 1. Coronary thrombolysis with recombinant tissue-type plasminogen activator. A hematologic and pharmacologic study.
    Topol EJ; Bell WR; Weisfeldt ML
    Ann Intern Med; 1985 Dec; 103(6 ( Pt 1)):837-43. PubMed ID: 3933395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombolysis in myocardial infarction (TIMI): comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator.
    Mueller HS; Rao AK; Forman SA
    J Am Coll Cardiol; 1987 Sep; 10(3):479-90. PubMed ID: 3114349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrinogen breakdown, long-lasting systemic fibrinolysis, and procoagulant activation during alteplase double-bolus regimen in acute myocardial infarction.
    Stangl K; Laule M; Tenckhoff B; Stangl V; Gliech V; Dübel P; Grohmann A; Melzer C; Langel J; Wernecke KD; Baumann G; Ziemer S
    Am J Cardiol; 1998 Apr; 81(7):841-7. PubMed ID: 9555772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction.
    Collen D; Bounameaux H; De Cock F; Lijnen HR; Verstraete M
    Circulation; 1986 Mar; 73(3):511-7. PubMed ID: 2419009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamics of thrombolysis with recombinant tissue-type plasminogen activator. Correlation with characteristics of and clinical outcomes in patients with acute myocardial infarction. The TAMI Study Group.
    Stump DC; Califf RM; Topol EJ; Sigmon K; Thornton D; Masek R; Anderson L; Collen D
    Circulation; 1989 Nov; 80(5):1222-30. PubMed ID: 2509104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomised dose ranging study of recombinant tissue plasminogen activator in acute myocardial infarction.
    McNeill AJ; Shannon JS; Cunningham SR; Flannery DJ; Campbell NP; Khan MM; Patterson GC; Webb SW; Adgey AA
    Br Med J (Clin Res Ed); 1988 Jun; 296(6639):1768-71. PubMed ID: 3136831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of lipoprotein(a) on thrombolysis.
    von Hodenberg E; Pestel E; Kreuzer J; Freitag M; Bode C
    Chem Phys Lipids; 1994 Jan; 67-68():381-5. PubMed ID: 8187238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparative randomized study of the effectiveness of intravenous recombinant tissue-type plasminogen activator and intravenous streptokinase in patients with acute myocardial infarct. Report of the European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator].
    Verstraete M; Bory M; Collen D; Erbel R; Lennane RJ; Mathey D; Michels HR; Schartl M; Uebis R; Bernard R
    Klin Wochenschr; 1988; 66 Suppl 12():77-85. PubMed ID: 3126348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Variations in hemostasis and fibrinolysis during the treatment of acute myocardial infarct (AMI) with tissue-type plasminogen activator (TTPA). A study of 17 cases].
    Izaguirre Avila R; Ruiz de Chávez Cervantes A; Villavicencio R; Gómez Trigos A; Mar Chavira R; Spíndola Mdel C; Casanova JM
    Arch Inst Cardiol Mex; 1993; 63(3):235-40. PubMed ID: 8347053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of prothrombin accompanying thrombolysis with recombinant tissue-type plasminogen activator.
    Eisenberg PR; Sobel BE; Jaffe AS
    J Am Coll Cardiol; 1992 Apr; 19(5):1065-9. PubMed ID: 1552097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and effects on fibrinolytic and coagulation parameters of two doses of recombinant tissue-type plasminogen activator in healthy volunteers.
    Verstraete M; Su CA; Tanswell P; Feuerer W; Collen D
    Thromb Haemost; 1986 Aug; 56(1):1-5. PubMed ID: 3095944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrinolytic effects of intracoronary streptokinase administration in patients with acute myocardial infarction and coronary insufficiency.
    Cowley MJ; Hastillo A; Vetrovec GW; Fisher LM; Garrett R; Hess ML
    Circulation; 1983 May; 67(5):1031-8. PubMed ID: 6831667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring of hemostasis parameters during coronary thrombolysis with recombinant tissue-type plasminogen activator.
    Stump DC; Topol EJ; Chen AB; Hopkins A; Collen D
    Thromb Haemost; 1988 Apr; 59(2):133-7. PubMed ID: 2455358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative properties of two clinical preparations of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction.
    Garabedian HD; Gold HK; Leinbach RC; Johns JA; Yasuda T; Kanke M; Collen D
    J Am Coll Cardiol; 1987 Mar; 9(3):599-607. PubMed ID: 3102584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An in vitro study of the effects of t-PA and tranexamic acid on whole blood coagulation and fibrinolysis.
    Godier A; Parmar K; Manandhar K; Hunt BJ
    J Clin Pathol; 2017 Feb; 70(2):154-161. PubMed ID: 27445340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombolytic therapy with recombinant human tissue-type plasminogen activator: a comparison of two doses.
    Risius B; Graor RA; Geisinger MA; Zelch MG; Lucas FV; Young JR
    Radiology; 1987 Aug; 164(2):465-8. PubMed ID: 3110860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous recombinant tissue-type plasminogen activator in acute myocardial infarction.
    Gao R; Chen J; Kou W; Yao K; Xu Y; Lu Z; Yu Q; Tao P; Ma J; Zhu J
    Chin Med Sci J; 1991 Sep; 6(3):132-5. PubMed ID: 1793874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Laboratory monitoring of hemostasis during thrombolytic therapy with recombinant human tissue-type plasminogen activator.
    Garabedian HD; Gold HK; Leinbach RC; Yasuda T; Johns JA; Thornton D; Collen D
    Thromb Res; 1988 Apr; 50(1):121-33. PubMed ID: 3135634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant human C1-inhibitor prevents non-specific proteolysis by mutant pro-urokinase during optimal fibrinolysis.
    Gurewich V; Pannell R
    Thromb Haemost; 2009 Aug; 102(2):279-86. PubMed ID: 19652878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-ranging study with a new two-chain rt-PA in patients with acute myocardial infarction: a multicenter trial.
    DeWood MA; Kurnik PB; Jolly MK; Jain AC; Khaja F; Gorfinkel HJ; Morris DL; Satler L; LittleJohn J
    Clin Cardiol; 1993 Apr; 16(4):302-10. PubMed ID: 8458110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.